 Prognostic factors survival patients advanced urothelial tumors methotrexate vinblastine doxorubicin cisplatin chemotherapy Between February February patients advanced urothelial tract tumors methotrexate vinblastine Adriamycin doxorubicin cisplatin M-VAC chemotherapy Analysis prognostic factors survival first patients undertaken Cox proportional hazards model Normal alkaline phosphatase high Karnofsky performance status KPS predominant long survival years initiation therapy likely patients physician selectivity patients therapy initial hemoglobin normal range likely additional patients data model Clinical implications prognostic factors